• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Sinovac's COVID-19 vaccine 58.5% effective in preventing illness -Chile real world study

firstwordpharmaAugust 04, 2021

Tag: Sinovac , COVID-19 , Vaccine

Chilean health authorities said on Tuesday that Sinovac's COVID-19 vaccine was 58.5% effective in preventing symptomatic infection among millions of Chileans who received it between February and July, as reported This is Money

Sinovac's COVID-19 vaccine 58.5% effective in preventing illness -Chile real world study

Coronavac was 86% effective in preventing hospitalisation, 89.7% effective in preventing intensive care unit admission and 86% effective in preventing deaths within the population, said health official Rafael Araos.


Previous:Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Next:Rupture Disc Market in Industrial Machinery Industry | COVID-19 Impact & Recovery Analysis | Technavio

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Sinovac's COVID-19 vaccine 58.5% effective in preventing illness -Chile real world study | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Enterovirus Type 71 Vaccine, Inactivated (Human Diploid Cell)

Enterovirus Type 71 Vaccine, Inactivated (Human Diploid Cell)
Hualan Bio-H7N9 Inactivated Influenza Vaccine

Hualan Bio-H7N9 Inactivated Influenza Vaccine
high quality and standard Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological

high quality and standard Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological
H7N9 Inactivated Influenza Vaccine-HUALAN BIO

H7N9 Inactivated Influenza Vaccine-HUALAN BIO
flu vaccine for 2023-2024 northern hemisphere influenza season

flu vaccine for 2023-2024 northern hemisphere influenza season
Hualan Influenza Vaccine

Hualan Influenza Vaccine
Influenza Vaccine(Split Virion),Inactivated

Influenza Vaccine(Split Virion),Inactivated
Hualan H7N9 Inactivated Influenza Vaccine by Hualan Bio

Hualan H7N9 Inactivated Influenza Vaccine by Hualan Bio
23-valent Pneumococcal Polysaccharide vaccine

23-valent Pneumococcal Polysaccharide vaccine
high standard and safety Influenza A (H1N1) Vaccine, (Split, Inactivated)

high standard and safety Influenza A (H1N1) Vaccine, (Split, Inactivated)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service